Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Namodenoson in NASH
NCT04697810Phase 2Recruiting
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Dec 2021
- Primary completion
- Apr 2025
- Countries
- 6
01
Overview
A Phase 2 trial of namodenoson in Nonalcoholic steatohepatitis (NASH), sponsored by Can-Fite BioPharma Ltd.. Started Dec 2021; status: recruiting.
02
Drugs
namodenoson
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04697810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04697810.